Closed · RFA-DA-26-019 · CFDA 93.279 · Discretionary

Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
February 19, 2025
Close date
-
Expected awards

The verdict

Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

Varies
award range
Closed
application status
93.279
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Addressing Challenges in Detecting New Drugs:… is closed (last close February 19, 2025). The parent program page for CFDA 93.279 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed February 19, 2025

Posted Nov 4 Closes Feb 19

Instrument

Grant

Description

Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods.

Small-business / for-profit corridor · RFA-DA-26-019

Addressing Challenges in Detecting New Drugs:… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Parent Grant Program

CFDA 93.279

Drug Abuse Research Programs

National Institutes of Health

View program →

Agency Contact

NIH Grants Information grantsinfo@nih.gov

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

Addressing Challenges in Detecting New Drugs:… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.279 may publish future NOFOs under the same assistance listing. Open program
  • Drug Abuse Research Programs indexes 170 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants